REFERENCES
- Suwaki H. Methamphetamine abuse in Japan: its 45 year history and the current situation. Amphetamine misuse: international perspectives on current trends, H Klee. Harwood Academic, ReadingEngland 1997; 199–214
- Anglin M D, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs 2000; 32: 137–41, [PUBMED], [INFOTRIEVE], [CSA]
- Miller M A. History and epidemiology of methamphetamine abuse in the United States. Amphetamine misuse: international perspectives on current trends, H. Klee. Harwood Academic, ReadingEngland 1997; 113–34
- Morgan P, Beck J E. The legacy and the paradox: hidden contexts of methamphetamine use in the United States. Amphetamine misuse: international perspectives on current trends, H Klee. Harwood Academic, ReadingEngland 1997; 135–62
- National Drug Intelligence Center. Methamphetamine. National Drug Threat Assessment 2003, http://www.usdoj.gov/ ndic/pubs3/3300/meth.htm.
- U.S. Department of Justice. Report to the US Attorney General by the Suspicious Orders Task Force: Comprehensive Methamphetamine Control Act of 1996. 1999, http://www.deadiversion.usdoj.gov/pubs/program/sotf/
- Nordahl T E, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003; 15: 317–25, [PUBMED], [INFOTRIEVE], [CSA]
- Salocks C., Kaley K. Clandestine drug labs: methamphetamine [Technical support document: Toxicology]. 2003, At http://www.oehha.ca.gov/public_info/clanlabs.html
- Ely R, McGrath D. Lithium-ammonia reduction of ephedrine to methamphetamine: an unusual clandestine synthesis. J Forensic Sci 1990; 35: 720–3
- Gorelick D A, Cornish J L. The pharmacology of cocaine, amphetamines, and other stimulants. Principles of addiction medicine, A Graham, T Schultz, M Mayo-Smith, R Ries, B Wilford. American Society of Addiction Medicine, Chevy Chase, MD 2003; 157–90
- Office of National Drug Control Policy. Methamphetamine [Fact sheet]. 2003, At http://www.whitehousedrugpolicy.gov/ drugfact/index.html
- Feinstein D. Methamphetamine, the drug epidemic of the 90s: problems and solutions. 2002, http://feinstein.senate. gov/meth_booklet.html
- Office of Applied Statistics, Substance Abuse and Mental Health Services Administration. Summary of Findings from the 2000 National Household Survey on Drug Abuse. 2001, http://www.oas.samhsa.gov/NHSDA/2kNHSDA/ 2kNHSDA.htm
- Zhang Z. Drug and alcohol use and related matters among arrestees. Institute of Justice, U.S. Department of Justice. 2003, http://www.ojp.usdoj.gov/nij/adam/ADAM2003.pdf
- Community Epidemiology Work Group, National Institute on Drug Abuse. Epidemiologic trends in drug abuse, advance report. 2003,
- Woody G E, Cottler L B, Cacciola J. Severity of dependence: data from the DSM-IV field trials. Addiction 1993; 88: 1573–9, [PUBMED], [INFOTRIEVE]
- United Nations Office on Drug Control and Crime Prevention. World Drug Report 2000,
- Office of National Drug Control Policy. National Drug Control Strategy: update 2003, http://www.whitehousedrugpolicy. gov/publications/policy/ndcs03/table71.html
- Office of Applied Statistics, Substance Abuse and Mental Health Services Administration. Amphetamine and methamphetamine emergency department visits 1995–2002 [DAWN report]. 2004, At http://dawninfo.samhsa.gov/old_ dawn/pubs_94_02/shortreports/
- National Drug Intelligence Center. Information bulletin: children at risk. 2002, http://www.usdoj.gov/ndic/pubs1/1466/
- Kolecki P. Inadvertent methamphetamine poisoning inpediatric patients. Pediatr Emerg Care 1998; 14: 385–7, [PUBMED], [INFOTRIEVE], [CSA]
- National Institute on Drug Abuse. Methamphetamine abuse and addiction [Research Report series]. 1998, http://165.112. 78.61/ResearchReports/Methamph/methamph4.html
- Eriksson M, Larsson G, Winbladh B, Zetterstrom R. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand 1978; 67: 95–9, [PUBMED], [INFOTRIEVE]
- Eriksson M, Larsson G, Zetterstrom R. Amphetamine addiction and pregnancy. II. Pregnancy, delivery and the neonatal period. Socio-medical aspects. Acta Obstet Gynecol Scand 1981; 60: 253–9, [PUBMED], [INFOTRIEVE]
- Dixon S D, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates. J Pediatr 1989; 115: 770–8, [PUBMED], [INFOTRIEVE]
- Plessinger M A. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998; 25: 119–38, [PUBMED], [INFOTRIEVE], [CSA]
- Smith L, Yonekura M L, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr 2003; 24: 17–23, [PUBMED], [INFOTRIEVE], [CSA]
- Hansen R L, Struthers J M, Gospe S M, Jr. Visual evoked potentials and visual processing in stimulant drug-exposed infants. Dev Med Child Neurol 1993; 35: 798–805, [PUBMED], [INFOTRIEVE]
- Billing L, Eriksson M, Steneroth G, Zetterstrom R. Predictive indicators for adjustment in 4-year-old children whose mothers used amphetamine during pregnancy. Child Abuse Negl 1988; 12: 503–7, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Billing L, Eriksson M, Jonsson B, Steneroth G, Zetterstrom R. The influence of environmental factors on behavioural problems in 8-year-old children exposed to amphetamine during fetal life. Child Abuse Negl 1994; 18: 3–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Eriksson M, Billing L, Steneroth G, Zetterstrom R. Health and development of 8-year-old children whose mothers abused amphetamine during pregnancy. Acta Paediatr Scand 1989; 78: 944–9, [PUBMED], [INFOTRIEVE]
- Eriksson M, Jonsson B, Steneroth G, Zetterstrom R. Amphetamine abuse during pregnancy: environmental factors and outcome after 14–15 years. Scand J Public Health 2000; 28: 154–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Billing L, Eriksson M, Steneroth G, Zetterstrom R. Pre-school children of amphetamine-addicted mothers. I. Somatic and psychomotor development. Acta Paediatr Scand 1985; 74: 179–84, [PUBMED], [INFOTRIEVE]
- Eriksson M, Zetterstrom R. Amphetamine addiction during pregnancy: 10-year follow-up. Acta Paediatr Suppl 1994; 404: 27–31, [PUBMED], [INFOTRIEVE], [CSA]
- Chang L, Smith L M, Lopresti C, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res 2004; 132: 95–106, [PUBMED], [INFOTRIEVE]
- Bluthenthal R N, Kral A H, Gee L, et al. Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000. J Acquir Immune Defic Syndr 2001; 28: 264–9, [PUBMED], [INFOTRIEVE]
- Harris N V, Thiede H, McGough J P, Gordon D. Risk factors for HIV infection among injection drug users: results of blinded surveys in drug treatment centers, King County, Washington 1988–1991. J Acquir Immune Defic Syndr 1993; 6: 1275–82, [PUBMED], [INFOTRIEVE]
- Halkitis P N, Parsons J T, Stirratt M J. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex 2001; 41: 17–35, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Paul J P, Stall R, Davis F. Sexual risk for HIV transmission among gay/bisexual men in substance-abuse treatment. AIDS Educ Prev 1993; 5: 11–24, [PUBMED], [INFOTRIEVE], [CSA]
- Frosch D, Shoptaw S, Huber A, Rawson R A, Ling W., Sexual H IV. risk among gay and bisexual male methamphetamine abusers. J Subst Abuse Treat 1996; 13: 483–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shoptaw S, Reback C J, Freese T E. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis 2002; 21: 91–105, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lake C R, Quirk R S. CNS stimulants and the look-alike drugs. Psychiatr Clin North Am 1984; 7: 689–701, [PUBMED], [INFOTRIEVE]
- Giros B, Jaber M, Jones S R, Wightman R M, Caron M G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606–12, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fumagalli F, Gainetdinov R R, Valenzano K J, Caron M G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 1998; 18: 4861–9, [PUBMED], [INFOTRIEVE]
- Cho A K, Melega W P. Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002; 21: 21–34, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rawson R A, Huber A, Brethen P, et al. Status of methamphetamine users 2–5 years after outpatient treatment. J Addict Dis 2002; 21: 107–19, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cho A K, Melega W P, Kuczenski R, Segal D S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 2001; 39: 161–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rawson R, Huber A, Brethen P, et al. Methamphetamine and cocaine users: differences in characteristics and treatment retention. J Psychoactive Drugs 2000; 32: 233–8, [PUBMED], [INFOTRIEVE], [CSA]
- Gawin F H, Ellinwood E H, Jr. Cocaine and other stimulants. Actions, abuse, and treatment. N Engl J Med 1988; 318: 1173–82, [PUBMED], [INFOTRIEVE], [CSA]
- Gawin F, ME K, Ellinwood E. Stimulants. Textbook of substance abuse treatment, M Galanter, H Kleber. American Psychiatric Press, Washington, DC 1994
- Cretzmeyer M, Sarrazin M V, Huber D L, Block R I, Hall J A. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 2003; 24: 267–77, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cantwell B, McBride A J. Self detoxication by amphetamine dependent patients: a pilot study. Drug Alcohol Depend 1998; 49: 157–63, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Newton T, Kalechstein A D, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 2004; 13: 248–55, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ellinwood E, King G, Lee T. Chronic amphetamine use and abuse. Psychopharmacology: the fourth generation of progress [CD-ROM version], S Watson. Wilkins & Williams, Philadelphia, Lippincott 1998
- Davidson C, Gow A J, Lee T H, Ellinwood E H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001; 36: 1–22, [PUBMED], [INFOTRIEVE], [CSA]
- Hotchkiss A J, Gibb J W. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 1980; 214: 257–62, [PUBMED], [INFOTRIEVE]
- Ricaurte G A, Schuster C R, Seiden L S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 1980; 193: 153–63, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ricaurte G A, Guillery R W, Seiden L S, Schuster C R, Moore R Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 1982; 235: 93–103, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ricaurte G A, Seiden L S, Schuster C R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 1984; 303: 359–64, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ryan L J, Linder J C, Martone M E, Groves P M. Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res 1990; 518: 67–77, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wagner G C, Ricaurte G A, Johanson C E, Schuster C R, Seiden L S. Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology 1980; 30: 547–50, [PUBMED], [INFOTRIEVE]
- Wagner G C, Ricaurte G A, Seiden L S, Schuster C R, Miller R J, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 1980; 181: 151–60, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Koda L Y, Gibb J W. Adrenal and striatal tyrosine hydroxylase activity after methamphetamine. J Pharmacol Exp Ther 1973; 185: 42–8, [PUBMED], [INFOTRIEVE]
- Schmidt C J, Gibb J W. Role of the serotonin uptake carrier in the neurochemical response to methamphetamine: effects of citalopram and chlorimipramine. Neurochem Res 1985; 10: 637–48, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wagner G C, Preston K, Ricaurte G A, Schuster C R, Seiden L S. Neurochemical similarities between d,l-cathinone and d-amphetamine. Drug Alcohol Depend 1982; 9: 279–84, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Frey K, Kilbourn M, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 1997; 334: 273–9, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Harvey D C, Lacan G, Tanious S P, Melega W P. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 2000; 871: 259–70, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cass W A, Manning M W. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 1999; 19: 7653–60, [PUBMED], [INFOTRIEVE]
- Cass W A. Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic doses of methamphetamine. J Neurochem 2000; 74: 1079–85, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Friedman S D, Castaneda E, Hodge G K. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1998; 61: 35–44, [PUBMED], [INFOTRIEVE], [CSA]
- Melega W P, Quintana J, Raleigh M J, et al. 6-[18F]fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse 1996; 22: 63–9, [PUBMED], [INFOTRIEVE], [CSA]
- Melega W P, Raleigh M J, Stout D B, Huang S C, Phelps M E. Ethological and 6-[18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine. Behav Brain Res 1997; 84: 259–68, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Woolverton W L, Ricaurte G A, Forno L S, Seiden L S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 1989; 486: 73–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jaffe J. Drug addiction and drug abuse. Pharmacological basis of therapeutics, L Goodman, S Gilman. McMillan, New York 1985
- Simon S L, Richardson K, Dacey J, et al. A comparison of patterns of methamphetamine and cocaine use. J Addict Dis 2002; 21: 35–44, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Villemagne V, Yuan J, Wong D F, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998; 18: 419–27, [PUBMED], [INFOTRIEVE]
- McCann U D, Wong D F, Yokoi F, Villemagne V, Dannals R F, Ricaurte G A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18: 8417–22, [PUBMED], [INFOTRIEVE]
- Wilson J M, Kalasinsky K S, Levey A I, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2: 699–703, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Moszczynska A, Fitzmaurice P, Ang L, et al. Why is parkinsonism not a feature of human methamphetamine users?. Brain 2004; 127: 363–70, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gibb J W, Kogan F J. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch Pharmacol 1979; 310: 185–7, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schmidt C J, Ritter J K, Sonsalla P K, Hanson G R, Gibb J W. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 1985; 233: 539–44, [PUBMED], [INFOTRIEVE]
- Johnson M, Stone D M, Hanson G R, Gibb J W. Role of the dopaminergic nigrostriatal pathway in methamphetamine-induced depression of the neostriatal serotonergic system. Eur J Pharmacol 1987; 135: 231–4, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Axt K J, Commins D L, Vosmer G, Seiden L S. alpha-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res 1990; 515: 269–76, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seiden L S, Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav 1984; 21: 29–31, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cadet J L, Sheng P, Ali S, Rothman R, Carlson E, Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 1994; 62: 380–3, [PUBMED], [INFOTRIEVE]
- De Vito M J, Wagner G C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 1989; 28: 1145–50, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hirata H, Ladenheim B, Carlson E, Epstein C, Cadet J L. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res 1996; 714: 95–103, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Maragos W F, Jakel R, Chesnut D, et al. Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase. Brain Res 2000; 878: 218–22, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Itzhak Y, Ali S F. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem 1996; 67: 1770–3, [PUBMED], [INFOTRIEVE]
- Itzhak Y, Martin J L, Black M D, Ali S F. Effect of melatonin on methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neuropharmacology 1998; 37: 781–91, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wagner G C, Carelli R M, Jarvis M F. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology 1986; 25: 559–61, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hastings T G, Lewis D A, Zigmond M J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 1996; 93: 1956–61, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rumbaugh C. Small vessel cerebral vascular changes following chronic methamphetamine intoxication. Cocaine and other stimulants, E H Ellinwood, Jr, M M Kilbey. Plenum, New York 1977
- Jackson J G. The hazards of smokable methamphetamine. N Engl J Med 1989; 321: 907, [PUBMED], [INFOTRIEVE], [CSA]
- Karch S B, Stephens B G, Ho C H. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 1999; 44: 359–68, [PUBMED], [INFOTRIEVE]
- Shaw K P. Human methamphetamine-related fatalities in Taiwan during 1991–1996. J Forensic Sci 1999; 44: 27–31, [PUBMED], [INFOTRIEVE]
- Swalwell C I, Davis G G. Methamphetamine as a risk factor for acute aortic dissection. J Forensic Sci 1999; 44: 23–6, [PUBMED], [INFOTRIEVE]
- King G, Ellinwood E. Amphetamine and other stimulants. Substance abuse: a comprehensive textbook, Lowinson, Ruiz, Milman, Langrod. Williams & Wilkins, Baltimore, MD 1997
- Richards J R, Bretz S W, Johnson E B, Turnipseed S D, Brofeldt B T, Derlet R W. Methamphetamine abuse and emergency department utilization. West J Med 1999; 170: 198–202, [PUBMED], [INFOTRIEVE], [CSA]
- Alldredge B K, Lowenstein D H, Simon R P. Seizures associated with recreational drug abuse. Neurology 1989; 39: 1037–9, [PUBMED], [INFOTRIEVE]
- Olson K R, Kearney T E, Dyer J E, Benowitz N L, Blanc P D. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993; 11: 565–8, [CROSSREF]
- Logan B K. Methamphetamine and driving impairment. J Forensic Sci 1996; 41: 457–64, [PUBMED], [INFOTRIEVE]
- Alexander G E, De Long M R, Strick P L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357–81, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wilson J M, Levey A I, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996; 47: 718–26, [PUBMED], [INFOTRIEVE], [CSA]
- Kish S J, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876–80, [CSA]
- Ellinwood E. Amphetamine psychosis. I. Description of the individuals and the process. J Nerv Ment Dis 1967; 144: 273
- Batki S L, Harris D. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict 2004; 13: 461–70, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bailey D N, Shaw R F. Cocaine- and methamphetamine-related deaths in San Diego County (1987): homicides and accidental overdoses. J Forensic Sci 1989; 34: 407–22, [PUBMED], [INFOTRIEVE]
- Fukushima A. Criminal responsibility in amphetamine psychosis. Jpn J Psychiatry Neurol 1994; 1–4, 48 suppl
- Lora-Tamayo C, Tena T, Rodriguez A. Amphetamine derivative related deaths. Forensic Sci Int 1997; 85: 149–57, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Logan B K, Fligner C L, Haddix T. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 1998; 43: 28–34, [PUBMED], [INFOTRIEVE]
- Shaw K, Chung J. Methamphetamine and opiate-related fatalities in Taiwan Forensic Medicine Center in 1996. Narc Bull (Taiwan) 1997; 2: 1–14
- Buffenstein A, Heaster J, Ko P. Chronic psychotic illness from methamphetamine. Am J Psychiatry 1999; 156: 662, [PUBMED], [INFOTRIEVE]
- Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158: 1206–14, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zweben J E, Cohen J B, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13: 181–90, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- London E D, Simon S L, Berman S M, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 2004; 61: 73–84, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kalechstein A D, Newton T F, Longshore D, Anglin M D, van Gorp W G, Gawin F H. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 2000; 12: 480–4, [PUBMED], [INFOTRIEVE], [CSA]
- Simon S L, Domier C, Carnell J, Brethen P, Rawson R, Ling W. Cognitive impairment in individuals currently using methamphetamine. Am J Addict 2000; 9: 222–31, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Volkow N D, Chang L, Wang G J, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377–82, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kalechstein A D, Newton T F, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 2003; 15: 215–20, [PUBMED], [INFOTRIEVE], [CSA]
- Iyo M, Sekine Y, Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann NY Acad Sci 2004; 1025: 288–95, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Brain Res Rev 1994; 19: 223–39, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Principles of addiction medicine. 3rd ed., A W Graham, T K Schultz, M F Mayo-Smith, R K Ries, B B Wilford. American Society of Addiction Medicine, Chevy Chase, MD 2003
- Harris D, Batki S L. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 2000; 9: 28–37, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chen C K, Lin S K, Sham P C, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med 2003; 33: 1407–14, [PUBMED], [INFOTRIEVE]
- Ujike H, Harano M, Inada T, et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003; 3: 242–7, [PUBMED], [INFOTRIEVE], [CSA]
- Koizumi H, Hashimoto K, Kumakiri C, et al. Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. Am J Med Genet 2004; 126B: 43–5, [CROSSREF]
- Kobayashi H, Ide S, Hasegawa J, et al. Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann NY Acad Sci 2004; 1025: 325–34, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fujii D. Risk factors for treatment-resistive methamphetamine psychosis. J Neuropsychiatry Clin Neurosci 2002; 14: 239–40, [PUBMED], [INFOTRIEVE], [CSA]
- Yui K, Ishiguro T, Goto K, Ikemoto S, Kamata Y. Spontaneous recurrence of methampetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur Arch Psychiatry Clin Neurosci 1999; 249: 103–11, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sato M, Chen C C, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18: 429–40, [PUBMED], [INFOTRIEVE]
- Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. Am J Psychiatry 1997; 154: 1170, [PUBMED], [INFOTRIEVE]
- Misra L K, Kofoed L, Oesterheld J R, Richards G A. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol 2000; 20: 393–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Saxon A J, Straits-Troster K, Rippeth J D, Romwall L, Rosenbaum G, Bush K R. Longitudinal cognitive changes among methamphetamine dependent patients in early abstinence. Presented at annual meeting of College on Problems of Drug Dependence, Bal Harbour, FL, June, 2003
- Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry 2000; 176: 285–9, [CSA]
- Sim T, Simon S L, Domier C P, Richardson K, Rawson R A, Ling W. Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis 2002; 21: 75–89, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jaffe C, Bush K R, Straits-Troster K, et al. A comparison of methamphetamine-dependent inpatients with and without childhood attention deficit hyperactivity disorder symptomatology. J Addict Dis, (in press)
- Clure C, Brady K T, Saladin M E, Johnson D, Waid R, Rittenbury M. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse 1999; 25: 441–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wilens T E, Prince J B, Biederman J, Spencer T J, Frances R J. Attention-deficit hyperactivity disorder and comorbid substance use disorders in adults. Psychiatr Serv 1995; 46: 761–3, 765[PUBMED], [INFOTRIEVE], [CSA]
- Hill J C, Schoener E P. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1143–6, [PUBMED], [INFOTRIEVE]
- Faraone S V, Biederman J, Spencer T, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000; 48: 9–20, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Biederman J, Mick E, Faraone S V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jentsch J D, Roth R H, Taylor J R. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Prog Brain Res 2000; 126: 433–53, [PUBMED], [INFOTRIEVE], [CSA]
- Previc F H. Dopamine and the origins of human intelligence. Brain Cogn 1999; 41: 299–350, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Barkley R A, Grodzinsky G, Du Paul G J. Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. J Abnorm Child Psychol 1992; 20: 163–88, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Barkley R A. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain Dev 2003; 25: 77–83, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seidman L J, Biederman J, Weber W, Hatch M, Faraone S V. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 260–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kempton S, Vance A, Maruff P, Luk E, Costin J, Pantelis C. Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med 1999; 29: 527–38, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58: 775–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wilens T E, Spencer T J, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158: 282–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wilens T E, Faraone S V, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179–85, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ward M F, Wender P H, Rieimherr F W. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit disorder. Am J Psychiatry 1993; 150: 885–90, [PUBMED], [INFOTRIEVE]
- Mohs R C, Tinklenberg J R, Roth W T, Kopell B S. Methamphetamine and diphenhydramine effects on the rate of cognitive processing. Psychopharmacology 1978; 59: 13–9, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Carpenter J A. The effect of caffeine and alcohol on simple visual reaction time. J Comp Physiol Psychol 1959; 52: 491–6, [PUBMED], [INFOTRIEVE]
- Soetens E, Casaer S, D'Hooge R, Hueting J E. Effect of amphetamine on long-term retention of verbal material. Psychopharmacology 1995; 119: 155–62, [PUBMED], [INFOTRIEVE]
- McKetin R, Mattick R P. Attention and memory in illicit amphetamine users. Drug Alcohol Depend 1997; 48: 235–42, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McKetin R, Mattick R P. Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend 1998; 50: 181–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Simon S L, Domier C P, Sim T, Richardson K, Rawson R A, Ling W. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 2002; 21: 61–74, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ornstein T J, Iddon J L, Baldacchino A M, et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000; 23: 113–26, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Salo R, Nordahl T E, Possin K, et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res 2002; 111: 65–74, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Simon S L, Dacey J, Glynn S, Rawson R, Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat 2004; 27: 59–66, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Volkow N D, Chang L, Wang G J, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21: 9414–8, [PUBMED], [INFOTRIEVE]
- Chang L, Ernst T, Speck O, et al. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 2002; 114: 65–79, [PUBMED], [INFOTRIEVE]
- Di Sclafani V, Tolou-Shams M, Price L J, Fein G. Neuropsychological performance of individuals dependent on crack-cocaine, or crack-cocaine and alcohol, at 6 weeks and 6 months of abstinence. Drug Alcohol Depend 2002; 66: 161–71, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Beatty W W, Katzung V M, Moreland V J, Nixon S J. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend 1995; 37: 247–53, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Berry J, van Gorp W G, Herzberg D S, et al. Neuropsychological deficits in abstinent cocaine abusers: preliminary findings after two weeks of abstinence. Drug Alcohol Depend 1993; 32: 231–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Selby M J, Azrin R L. Neuropsychological functioning in drug abusers. Drug Alcohol Depend 1998; 50: 39–45, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mash D C, Pablo J, Ouyang Q, Hearn W L, Izenwasser S. Dopamine transport function is elevated in cocaine users. J Neurochem 2002; 81: 292–300, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Little K Y, Zhang L, Desmond T, Frey K A, Dalack G W, Cassin B J. Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry 1999; 156: 238–45, [PUBMED], [INFOTRIEVE]
- Malison R T, Best S E, Wallace E A, et al. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) 1995; 122: 358–62, [CSA]
- Malison R T, Best S E, van Dyck C H, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 1998; 155: 832–4, [PUBMED], [INFOTRIEVE]
- Harvey D C, Lacan G, Melegan W P. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp Brain Res 2000; 133: 349–58, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laakso A, Vilkman H, Kajander J, et al. Prediction of detached personality in healthy subjects by low dopamine transporter binding. Am J Psychiatry 2000; 157: 290–2, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Volkow N D, Wang G J, Fowler J S, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999; 156: 19–26, [PUBMED], [INFOTRIEVE]
- Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 2000; 54: 1344–9, [PUBMED], [INFOTRIEVE], [CSA]
- Sekine Y, Minabe Y, Kawai M, et al. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology 2002; 27: 453–61, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nordahl T E, Salo R, Possin K, et al. Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy. Psychiatry Res 2002; 116: 43–52, [PUBMED], [INFOTRIEVE]
- Paulus M P, Hozack N E, Zauscher B E, et al. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 2002; 26: 53–63, [PUBMED], [INFOTRIEVE], [CSA]
- Thompson P M, Hayashi K M, Simon S L, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004; 24: 6028–36, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Frawley P J, Smith J W. One-year follow-up after multimodal inpatient treatment for cocaine and methamphetamine dependencies. J Subst Abuse Treat 1992; 9: 271–86, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rawson R, Obert J, McCann M. The neurobehavioral treatment manual. Matrix, Beverly Hills, CA 1989
- Rawson R A, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 2002; 23: 145–50, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Huber A, Ling W, Shoptaw S, Gulati V, Brethen P, Rawson R. Integrating treatments for methamphetamine abuse: a psychosocial perspective. J Addict Dis 1997; 16: 41–50, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Srisurapanont M, Kittiratanapaiboon P, Jarusuraisin N. Treatment for amphetamine psychosis. Cochrane Database Syst Rev 2001; CD003026, [CSA]
- Galloway G P, Newmeyer J, Knapp T, Stalcup S A, Smith D. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994; 13: 201–16, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Galloway G P, Newmeyer J, Knapp T, Stalcup S A, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996; 13: 493–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shoptaw S, Rawson R A, McCann M J, Obert J L. The Matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis 1994; 13: 129–41, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Batki S, Moon J, Bradley M, et al. Fluoxetine and methamphetamine dependence—a controlled trial: preliminary analysis. NIDA Res Monogr 1999; 180: 235
- Johnson B A, Roache J D, Bordnick P S, Ait-Daoud N. Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. Psychopharmacology 1999; 144: 295–300, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brodie J D, Figueroa E, Dewey S L. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003; 50: 261–5, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Brodie J D, Figueroa E, Laska E M, Dewey S L. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55: 122–5, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Arnt J. Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats. Behav Pharmacol 1992; 3: 11–8, [PUBMED], [INFOTRIEVE]
- Arnt J. Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?. Psychopharmacology (Berl) 1996; 124: 117–25, [CSA]
- Mechanic J A, Wasielewski J A, Carl K L, Holloway F A. Attenuation of the amphetamine discriminative cue in rats with the atypical antipsychotic olanzapine. Pharmacol Biochem Behav 2002; 72: 767–77, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rush C R, Stoops W W, Hays L R, Glaser P E, Hays L S. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306: 195–204, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Newton T F, Ling W, Kalechstein A D, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 2001; 102: 227–33, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Saxon A J, Jaffe C, Meredith C, et al. Open-label trial of risperidone for methamphetamine dependence. Presented at annual meeting of College on Problems of Drug Dependence, Orlando, FL, June, 2005
- Bilder R M, Goldman R S, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–28, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weickert T W, Goldberg T E, Marenco S, Bigelow L B, Egan M F, Weinberger D R. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003; 28: 1491–1500, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]